Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Greaves, Wesley ^a   Xiao, Lianchun ^a   Sanchez Espiridion, Beatriz ^a   Kunkalla, Kranthi ^a   Dave, Kunal S ^a   Liang, Cynthia S ^a   Singh, Rajesh R ^a   Younes, Anas ^a   Medeiros, L Jeffrey ^a   Vega, Francisco ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

ABCC1; ATP binding cassettes; Classical Hodgkin lymphoma; Immunohistochemistry

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C1; ABC TRANSPORTER C2; ABC TRANSPORTER C3; ALBUMIN; BLEOMYCIN; BREAST CANCER RESISTANCE PROTEIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; HEMOGLOBIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISONE; PROCARBAZINE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG TREATMENT FAILURE; FEMALE; GENE OVEREXPRESSION; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; REED STERNBERG CELL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CELL LINE, TUMOR; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; TREATMENT FAILURE; VINBLASTINE; YOUNG ADULT;

EID: 84864762788     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-47     Document Type: Article

References (21)

1. Developments in the management of Hodgkins lymphoma. Lowry L, Hoskin P, Linch D, Lancet 2010 375 786 788 10.1016/S0140-6736(09)61878-X 20171729
2. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Jona A, Younes A, Blood Rev 2010 24 233 238 10.1016/j.blre.2010.08.003 20828898
3. Long-term cause-specific mortality of patients treated for Hodgkins disease. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Vant Veer MB, Bartelink H, van Leeuwen FE, J Clin Oncol 2003 21 3431 3439 10.1200/JCO.2003.07. 131 12885835
4. Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment. Hsi ED, Leuk Lymphom 2008 49 1668 1680 10.1080/10428190802163339
5. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkins lymphoma. Diepstra A, van Imhoff GW, Karim-Kos HE, van den Berg A, te Meerman GJ, Niens M, et al. J Clin Onco 2007 25 3101 3108 10.1200/JCO.2006.10.0917
6. Expression of bcl-2 in classical Hodgkins lymphoma: an independent predictor of poor outcome. Sup SJ, Alemany CA, Pohlman B, Elson P, Malhi S, Thakkar S, et al. J Clin Oncol 2005 23 3773 3779 10.1200/JCO.2005.04.358 15809450
7. MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis. Hsi ED, Sup SJ, Alemany C, Tso E, Skacel M, Elson P, et al. Am J Clin Pathol 2006 125 776 782 10.1309/ 98KLHRDAM5CMDHE2 16707382
8. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, Viviani S, Bonfante V, Nadali G, et al. Blood 2002 100 3935 3941 10.1182/blood.V100.12.3935 12433696
9. Influence of biologic markers on the outcome of Hodgkins lymphoma: a study by the Spanish Hodgkins Lymphoma Study Group. Montalban C, Garcia JF, Abraira V, Gonzalez-Camacho L, Morente MM, Bello JL, et al. J Clin Oncol 2004 22 1664 1673 10.1200/JCO.2004.06.105 15117989
10. Tumor-associated macrophages and survival in classic Hodgkins lymphoma. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. N Engl J Med 2010 362 875 885 10.1056/NEJMoa0905680 20220182
11. Multidrug resistance in cancer: role of ATP-dependent transporters. Gottesman MM, Fojo T, Bates SE, Nat Rev Cancer 2002 2 48 58 10.1038/nrc706 11902585
12. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J, Schinkel AH, Cancer Res 2000 60 5761 5766 11059771
13. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. van der Kolk DM, de Vries EG, van Putten WJ, Verdonck LF, Ossenkoppele GJ, Verhoef GE, et al. Clin Cancer Res 2000 6 3205 3214 10955805
14. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, et al. Blood 1999 94 1086 1099 10419902
15. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Singh RR, Kunkalla K, Qu C, Schlette E, Neelapu SS, Samaniego F, et al. Oncogene 2011 30 4874 4886 10.1038/onc.2011.195 21625222
16. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). Deeley RG, Cole SPC, FEBS 2006 580 1103 1111 10.1016/j.febslet.2005.12. 036
17. Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Steidl C, Telenius A, Shah SP, Farinha P, Barclay L, Boyle M, et al. Blood 2010 116 418 427 10.1182/blood-2009-12-257345 20339089
18. Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma. Kim JE, Singh RR, Cho-Vega JH, Drakos E, Davuluri Y, Khokhar FA, et al. Mod Pathol 2009 22 1312 1320 10.1038/modpathol.2009.98 19593328
19. A TaqMan low-density array to predict outcome in advanced Hodgkins lymphoma using paraffin-embedded samples. Sanchez-Espiridion B, Sanchez-Aguilera A, Montalban C, Martin C, Martinez R, Gonzalez-Carrero J, et al. Clin Cancer Res 2009 15 1367 1375 10.1158/1078-0432.CCR-08-1119 19228737
20. Early response to chemotherapy: a surrogate for final outcome of Hodgkins disease patients that should influence initial treatment length and intensity? Carde P, Koscielny S, Franklin J, Axdorph U, Raemaekers J, Diehl V, et al. Ann Oncol 2002 13 Suppl 1 86 91 10.1093/annonc/13.S1.86 12078910
21. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, et al. Cancer Res 1999 59 8 13 9892175